293 related articles for article (PubMed ID: 10234700)
1. Role of iron in optimizing responses of anemic cancer patients to erythropoietin.
Glaspy J; Cavill I
Oncology (Williston Park); 1999 Apr; 13(4):461-73; discussion 477-8, 483-8. PubMed ID: 10234700
[TBL] [Abstract][Full Text] [Related]
2. Supplemental Iron: A Key to Optimizing the Response of Cancer-Related Anemia to rHuEPO?
Henry DH
Oncologist; 1998; 3(4):275-278. PubMed ID: 10388116
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human erythropoietin in cancer-related anemia. Review of clinical evidence.
Crawford J
Oncology (Williston Park); 2002 Sep; 16(9 Suppl 10):41-53. PubMed ID: 12380954
[TBL] [Abstract][Full Text] [Related]
4. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies.
Henry DH; Abels RI
Semin Oncol; 1994 Apr; 21(2 Suppl 3):21-8. PubMed ID: 8202722
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin hyporesponsiveness: from iron deficiency to iron overload.
Tarng DC; Huang TP; Chen TW; Yang WC
Kidney Int Suppl; 1999 Mar; 69():S107-18. PubMed ID: 10084294
[TBL] [Abstract][Full Text] [Related]
6. Anemia of renal failure. Use of erythropoietin.
Humphries JE
Med Clin North Am; 1992 May; 76(3):711-25. PubMed ID: 1578966
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy.
Case DC; Bukowski RM; Carey RW; Fishkin EH; Henry DH; Jacobson RJ; Jones SE; Keller AM; Kugler JW; Nichols CR
J Natl Cancer Inst; 1993 May; 85(10):801-6. PubMed ID: 8487324
[TBL] [Abstract][Full Text] [Related]
8. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
Nissenson AR
Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
[TBL] [Abstract][Full Text] [Related]
9. Nononcologic use of human recombinant erythropoietin therapy in hospitalized patients.
Fischer MA; Morris CA; Winkelmayer WC; Avorn J
Arch Intern Med; 2007 Apr; 167(8):840-6. PubMed ID: 17452549
[TBL] [Abstract][Full Text] [Related]
10. Standard of care for cancer-related anemia: improving hemoglobin levels and quality of life.
Cortesi E; Gascón P; Henry D; Littlewood T; Milroy R; Pronzato P; Reinhardt U; Shasha D; Thatcher N; Wilkinson P
Oncology; 2005; 68 Suppl 1():22-32. PubMed ID: 15855813
[TBL] [Abstract][Full Text] [Related]
11. Guidelines for recombinant human erythropoietin therapy.
Eschbach JW; Adamson JW
Am J Kidney Dis; 1989 Aug; 14(2 Suppl 1):2-8. PubMed ID: 2667349
[TBL] [Abstract][Full Text] [Related]
12. Comparison of darbepoetin alfa and epoetin alfa in the management of anemia of critical illness.
Voils SA; Harpe SH; Brophy GM
Pharmacotherapy; 2007 Apr; 27(4):535-41. PubMed ID: 17381380
[TBL] [Abstract][Full Text] [Related]
13. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial.
Eschbach JW; Abdulhadi MH; Browne JK; Delano BG; Downing MR; Egrie JC; Evans RW; Friedman EA; Graber SE; Haley NR
Ann Intern Med; 1989 Dec; 111(12):992-1000. PubMed ID: 2688507
[TBL] [Abstract][Full Text] [Related]
14. Iron management during treatment with recombinant human erythropoietin in chronic renal failure.
Watson A
J Clin Pharmacol; 1993 Dec; 33(12):1134-8. PubMed ID: 8126248
[TBL] [Abstract][Full Text] [Related]
15. Investigation of the efficacy of a biogeneric recombinant human erythropoietin alfa in the management of renal anemia in patients on hemodialysis: a multi-center clinical trial.
Beiraghdar F; Panahi Y; Einollahi B; Nemati E; Ghadiani MH; Sahebkar A; Maghsoudi N; Marzony ET
Clin Lab; 2012; 58(7-8):737-45. PubMed ID: 22997974
[TBL] [Abstract][Full Text] [Related]
16. Effects of recombinant human erythropoietin (rHuEPO) on tumor control in patients with cancer-induced anemia.
Vaupel P; Dunst J; Engert A; Fandrey J; Feyer P; Freund M; Jelkmann W
Onkologie; 2005 Apr; 28(4):216-21. PubMed ID: 15840971
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of erythroid marrow response to recombinant human erythropoietin in patients with cancer anaemia.
Ponchio L; Beguin Y; Farina G; Pedrazzoli P; Pedrotti C; Poggi G; Rosti V; Bergamaschi G; Battistel V; Cazzola M
Haematologica; 1992; 77(6):494-501. PubMed ID: 1289186
[TBL] [Abstract][Full Text] [Related]
18. Impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis.
Jones M; Ibels L; Schenkel B; Zagari M
Kidney Int; 2004 Mar; 65(3):757-67. PubMed ID: 14871396
[TBL] [Abstract][Full Text] [Related]
19. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
Hertel J; Locay H; Scarlata D; Jackson L; Prathikanti R; Audhya P
Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531
[TBL] [Abstract][Full Text] [Related]
20. Iron balance following recombinant human erythropoietin therapy for anemia associated with chronic renal failure.
Hotta T; Ogawa H; Saito A; Ito A
Int J Hematol; 1991 Jun; 54(3):195-200. PubMed ID: 1747454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
